Innate Pharma S.A Current Ratio 2019-2021 | IPHA

Innate Pharma S.A current ratio from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Innate Pharma S.A Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.16B $0.05B 3.04
2020-12-31 $0.20B $0.05B 3.81
2020-06-30 $0.18B $0.09B 1.99
2019-12-31 $0.27B $0.14B 1.95
2019-06-30 $0.24B $0.11B 2.29
2018-12-31 $0.38B $0.23B 1.63
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.449B $0.080B
Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86